about
Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy.Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomasGlucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes.Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsDetection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.Clinical trials of viral therapy for malignant gliomas.Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.Molecular profiling of gliomas: potential therapeutic implications.Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction.Bevacizumab as first-line therapy for glioblastoma.Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients.Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.Current Perspectives in the Management of Brain Metastases.Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.Edge Contrast of the FLAIR Hyperintense Region Predicts Survival in Patients with High-Grade Gliomas following Treatment with BevacizumabInfliximab for treatment-refractory transverse myelitis following immune therapy and radiationDeferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacyAT-02INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)IT-05ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION
P50
Q33616632-C24AF894-18A2-4C84-8E05-A5DDA6F87B0CQ34426355-AF40FC84-71EB-4BBA-98C8-9C670E5B4C2FQ35577661-B913E9D1-8628-4525-BECF-B13575371C80Q36189141-F5D54C6E-FA85-4750-BD03-96C365AA6FBDQ36401831-25BF084D-8437-4662-B850-DD59491F8523Q36486875-C267272C-3A33-4CEC-9154-7DEB3F3893F1Q37225334-87C92A08-823A-4C66-9569-ECFCEAA1A5D9Q37714940-196581DC-4F93-41E8-97F4-FCFE13EDED07Q38153777-037EB17C-D222-4D9D-9096-D0BB72157108Q38221330-4668CF4F-7C63-487E-87D8-CA082A132103Q38539422-50863393-7B7F-46D6-9AAB-A4FBDC59BD5BQ38747896-40F4FCC4-3203-46BC-8B9B-9B99ABEF0AA0Q38926653-0505E1D3-A75F-49FB-85C0-0B9E1F5F9220Q39568969-82D248EB-41D0-458A-AAFA-817316765A5DQ40374512-5C126C58-C8E5-43EF-B778-05DCE2DB09D6Q40912066-BEFB0B84-62E9-40CB-A83D-9700C2274CB6Q41102898-F9FA091A-B459-4FDB-A6ED-8F5C02516474Q42702318-3DBBB59A-2100-4F14-96B1-D6C874292F97Q45939742-0BE29FAA-5C9F-4146-9980-610E9F35963DQ45952326-6D79459D-1A1C-469E-A38C-4C66B2188433Q46754264-8F5B2E78-645E-4A1F-BC66-BD03A5958C28Q57739391-9D361B95-B274-4D20-9B17-5C3ADA191A2AQ60936732-7BA57A60-0EAB-459C-9DAF-020F997B9C5CQ87655215-501A391E-67CE-4795-90F7-860459829F0EQ94352289-DCBE7A36-1EB2-4793-9F97-E99E093C542FQ94353507-1F4B4D11-1956-41F8-8E97-A5157233B452
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David E Piccioni
@ast
David E Piccioni
@en
David E Piccioni
@es
David E Piccioni
@sl
type
label
David E Piccioni
@ast
David E Piccioni
@en
David E Piccioni
@es
David E Piccioni
@sl
prefLabel
David E Piccioni
@ast
David E Piccioni
@en
David E Piccioni
@es
David E Piccioni
@sl
P106
P21
P31
P496
0000-0001-6006-0126